Samsung Biologics’ U.S.-based contracting business will be the CDMO’s sole remaining subsidiary following the spinoff. In a bid to allay conflict-of-interest concerns, Korean manufacturing giant Samsung Biologics is decoupling from its biosimilars development unit. Starting later this year, Samsung Bio will devote itself fully to contract manufacturing under a plan to spin off a new investment holding company that will oversee the drugmaker’s biosimilar subsidiary Samsung Bioepis.T

KFSHRC to lead Clinical Trials Targeting Aplastic Anemia and Graft vs. Host Disease Cellenkos to Support Local Cell and Gene Therapy Manufacturing at KFSHRC RIYADH, Saudi Arabia and HOUSTON, May 22, 2025 /PRNewswire/ -- King Faisal Specialist Hospital & Research Centre (KFSHRC) and Cellenkos® Inc., a Texas based clinical stage biotech company, have signed a strategic international memorandum of understanding (MOU) following the Saudi-U.S. Investment Forum 2025, underscoring KFSHRC's commitment t

BRUSSELS--(BUSINESS WIRE)--The 4th Annual MPS World Summit, hosted by the International MPS Society (IMPSS) and supported by EUROoCS, will take place in Brussels, Belgium this summer. This premier event will bring together over 1,500 global leaders in Microphysiological Systems (MPS) research, focusing on innovative applications in drug safety, disease modeling, and regulatory testing. It will showcase the latest breakthroughs and foster collaboration across multiple sectors of the biomedical an

A pioneering monoclonal antibody facility for Rwanda marks a pivotal step toward scalable, locally driven production of life-saving biologics across the African continentSAN FRANCISCO and KIGALI, Rwanda, May 22, 2025 (GLOBE NEWSWIRE) -- Bio Usawa, Inc., a biopharmaceutical company based in San Francisco, Kigali, and Nairobi, committed to expanding access to life-saving biologics in Africa and underserved regions, today announced an agreement with Pacific Environmental Technologies, Inc., a glo

Gilead Sciences will pay $3 million at the close of a deal with Hookipa Pharma and the remaining $7 million across a three-stage transfer plan.\n Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV resulting from the company’s long-running collaboration with Hookipa Pharma.The partners launched a phase 1a/1b trial of HB-400, an arenaviral therapeutic vaccine for chronic HBV back in 2023, while the biotech’s early-stage

Delivery Method: Via Email Reference #: 2851, CMS 654751 Product: Drugs Issuing Office: Center for Drug Evaluation and Research (CDER) United States Secondary Issuing Offices Dear Kunjal Joshi: The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter # 2851, CMS 654751. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA regulatory activities will further as

CARLSBAD, Calif., May 20, 2025 /PRNewswire/ -- Pictor, a global leader in multiplex proteomics solutions, is excited to announce the establishment of its U.S. headquarters in Carlsbad, California, marking a significant milestone in its strategic growth and commitment to advancing cutting-edge solutions for laboratories worldwide. This transformation solidifies Pictor Holdings Inc. as the parent company, which will continue to proudly operate its subsidiaries in New Zealand, India, and Australia.

Global business leader brings 40+ years of leadership across insurance, healthcare, and institutional strategy UltraSight is pushing the boundaries of what’s possible in cardiac care, using machine learning to bring diagnostic-quality imaging to more people, in more places.” — Mr. Peter Chang Soo Kim BOSTON, MA, UNITED STATES, May 22, 2025 / EINPresswire.com / -- UltraSight™ , a digital health leader using machine learning to transform cardiac imaging, today announced the appointment of Mr. Pete

Stem Health Plus Leads the Way in Healing with Advanced Wound Care Solutions WONDER LAKE, IL, UNITED STATES, May 22, 2025 / EINPresswire.com / -- Stem Health Plus continues to lead advanced wound management by offering innovative, clinically backed wound care solutions that support healing and improve patient outcomes. With a growing need for effective treatment of chronic skin conditions, surgical wounds, and burns, the company’s tailored approach ensures patients receive optimal care every ste

Real-World Analysis Shows Statistically Significant Reduction in Severe Bleeding and Transfusion Needs in CABG Patients on the Blood Thinner, Ticagrelor, with CytoSorbents Therapy PRINCETON, N.J., May 22, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today's presentation at EuroPCR 2025 of a new contemporary real-world data analysis highligh